Emergent BioSolutions price to sales ratio EBS
Market value divided by revenue over the last twelve months, since 2012.
- Today, Oct 23, 2026
- 0.4×
- 10-year median
- 2.0×
- Against its 10-year history
- 19th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 0.1× to 5.6×
- Peer median
- 1.5×
Emergent BioSolutions' price to sales ratio is 0.4× as of Oct 23, 2026.
That is below its ten-year median of 2.0×, lower than on 81% of days in the last ten years.
Over that time it ranged from 0.1× in Feb 2024 to 5.6× in Aug 2020.
The median for 10 large drugmakers of a similar size is 1.5×.
Price to sales ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.4× | 0.3× | 0.7× |
| 2025 | 0.2× | 0.2× | 0.6× |
| 2024 | 0.4× | 0.1× | 0.6× |
| 2023 | 0.1× | 0.1× | 0.5× |
| 2022 | 0.4× | 0.4× | 1.7× |
| 2021 | 1.4× | 1.0× | 5.0× |
| 2020 | 3.6× | 2.3× | 5.6× |
| 2019 | 2.7× | 2.4× | 4.8× |
| 2018 | 4.2× | 3.5× | 5.3× |
| 2017 | 3.7× | 2.3× | 3.7× |
| 2016 | 2.5× | 1.9× | 3.1× |
| 2015 | 3.1× | 2.4× | 3.1× |
| 2014 | 2.6× | 2.1× | 3.3× |
| 2013 | 2.8× | 1.7× | 2.8× |
| 2012 | 1.9× | 1.6× | 2.0× |
Against its peers
Companies in Drug Manufacturers - General nearest Emergent BioSolutions' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| EBSEmergent BioSolutions | 0.4× |
| NATRNatures Sunshine Products | 0.4× |
| ARVNArvinas | 1.5× |
| PBYIPuma Biotechnology | 2.5× |
| IRWDIronwood Pharmaceuticals | 1.5× |
| ZVRAZevra Therapeutics | 4.3× |
| CRMDCorMedix | 1.3× |
| COLLCollegium Pharmaceutical | 0.9× |
| ABUSArbutus Biopharma | 4.6× |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| OMEROmeros | n/m |
| Peer median | 1.5× |
Where Emergent BioSolutions ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Emergent BioSolutions
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.